ClinicalTrials.gg
Active, not recruitingNCT04174105FORTISUpdated Nov 10, 2026

Gene Transfer Study in Patients With Late Onset Pompe Disease

A Phase 1/2 interventional study of zocaglusagene nuzaparvovec in Pompe Disease (Late-onset), sponsored by Astellas Gene Therapies. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Astellas Gene Therapies (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Glycogen Storage Disease Type II with a site in United States — 11 open to participants now, 20 under way, 3 of them phase 3. Glycogen Storage Disease Type II · United States.

Enrollment
41st of 60
11 · median 18
Started
2020
with 2 others
Phase 1/2
13 of 93
2 open now
Primary completion
2035-02
later than 19 of 19 live
Registered
77th of 93
by date
Lead sponsor
2 of 93
Astellas Gene Therapies

Among the 93 studies in Glycogen Storage Disease Type II with a site in United States, this one is the 41st largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2020, is one of 13 in phase 1/2, reaches primary completion later than 19 of the 19 other live ones, and was the 77th registered.

Glycogen Storage Disease Type II

162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.

Browse Glycogen Storage Disease Type II studies →

Open to participants now

11 of the 93 studies in Glycogen Storage Disease Type II with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Glycogen Storage Disease Type II with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1/2 open-label, ascending dose, multicenter clinical study to evaluate the safety and efficacy of AT845 in adult (aged ≥ 18 years) subjects, ambulatory or nonambulatory, with Late Onset Pompe Disease (LOPD).

Read the detailed description

This study (FORTIS) will evaluate the safety and efficacy of an investigational gene replacement therapy, AT845, in adult subjects with LOPD. Subjects will receive a single dose of AT845 delivered via intravenous (IV) infusion.

Up to 3 nominal dose levels of AT845 are planned to be evaluated in this study. A single AT845 administration via IV infusion is planned for each subject. The initial dosing cohort received a single dose of 3x10\^13 vg/kg of AT845. The second dose cohort will receive a single dose of 6×10\^13 vg/kg. The third dose cohort will receive a single dose of 1×10\^14 vg/kg. Dose escalation between cohorts will be based on evaluations of safety and in consultation with the independent DMC.

There will be a core observation period of 48 weeks with scheduled visits and assessments. Following the conclusion of the core observation period, subjects will be seen every 6 months for a safety follow-up visit for up to 10 years postdose.

03

Conditions studied

  • Pompe Disease (Late-onset)

Keywords

  • LOPD
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is aged ≥ 18 years.
  • Participant has a documented clinical diagnosis of Pompe disease by genetic testing.
  • Participant has received enzyme replacement therapy (ERT) with rhGAA for the previous ≥ 2 years.
  • Participant has been on a stable standard dose (at least 20 mg/kg every 2 weeks) of ERT with rhGAA for at least the previous 6 months.
  • Participant or legally authorized representative(s) (LAR) (if applicable) provides written .
  • Participant and LAR(s) are willing and able to comply with study visits and study procedures.
  • Participant must agree to refrain from blood or blood products donation and sperm or egg donation from the time of AT845 administration until the later of 90 days or 3 consecutive negative viral shedding samples
  • Participants enrolled in previous protocol versions 1 through 9: Participant has upright FVC ≥ 30% of predicted normal value. Participants enrolled starting with protocol version 10 and subsequent amendments: Participant has upright FVC ≥ 30% and ≤ 85% of predicted normal value.
  • Participants enrolled starting with protocol version 10 and subsequent amendments: Participant who is able to ambulate ≥ 40 m without stopping and without the use of an assistive device. The use of an assistive device for community ambulation is acceptable. (Participants enrolled under previous protocol versions 1 through 9 will not be excluded if they do not meet this criterion during Rescreening visit).

Exclusion criteria

Exclusion Criteria:

  • Participant is currently participating in an interventional study or has received gene or cell therapy.
  • Participant tests positive for AAV8 antibodies with titers >1:20 neutralizing.
  • Participant has received immune-modulating agents within 90 days before dosing (use of inhaled is allowed); use of other concomitant medications to manage chronic conditions must have been stable for at least 30 days before dosing. Concomitant medications that may predispose the participant to peripheral neuropathy will be evaluated.
  • Participant has any laboratory values (other than those directly associated with LOPD [e.g., GAA, serum creatine kinase (CK)]) that would preclude participation in the study.
  • Participant has serological or viral load evidence of -1 or HIV-2.
  • Participant has received drugs for treatment of myopathy or neuropathy with therapy (e.g., corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, IV immunoglobulin, rituximab) within 3 months prior to starting the study
  • Participant has a high risk for a severe allergic reaction to rhGAA (ie, previous moderate to severe anaphylactic reaction to alglucosidase alfa or and/or a history of sustained high immunoglobulin G [IgG] antibody titers to alglucosidase alfa that suggests a high risk for an allergic reaction to ERT).
  • Participant has a history of to β2 agonist drugs such as albuterol, levalbuterol, bitolterol, pirbuterol, terbutaline, salmeterol, which contraindicates pulmonary function testing.
  • Participant has an active viral infection based on clinical observation.
  • Participant has a history of or concurrent medical condition other than Pompe disease that could jeopardize safety of the participant or impact study results.
  • Participant has a history of, or currently has, a clinically important cardiac condition, such as an echocardiogram (ECHO) with below 40% or has symptoms or signs of cardiomyopathy that precludes enrollment.
  • Participant has a to study drug or to corticosteroids, or has demonstrated hypersensitivity to any of the components of the study drug.
  • Participant tests positive for GAA antibodies with titers > 1:50,000 total
  • Participant has a history of hypersensitivity to MRI contrast agents including gadolinium.
  • Participant has a known hypersensitivity to local anesthetics such as lidocaine.
  • Participant has a bleeding diathesis, e.g., due to anti-coagulation or anti- treatments.
  • Participant has a concurrent medical condition (including uncontrolled diabetes, alcohol use disorder, certain conditions, Lyme disease, active requiring chemotherapy and/or radiation, uremic nephropathy, known exposure to heavy metals) commonly associated with peripheral neuropathy. Other concurrent medical conditions that may predispose to peripheral neuropathy will be evaluated and action taken on a case-by-case basis, following discussion between the Investigator and Medical Monitor.
  • Participant who is unwilling to withdraw from ERT.
  • Participant has an active symptomatic large fiber peripheral neuropathy diagnosed by a neurologist at a screening visit.
  • Age-related sensory changes on NCS without symptoms or mononeuropathy (refers to focal involvement of a single nerve, usually due to a local cause such as trauma, compression or entrapment) will not be excluded.
  • Participant has clinically significant underlying liver disease at Screening, or has any of the following:
  • (ALT) > 2 × (ULN)
  • Aspartate aminotransferase (AST) > 2 × ULN
  • Total > 1.5 × ULN
  • Alkaline phosphatase (ALP) > 2 × ULN
  • ALT and AST are often higher than the normal range in Pompe disease patients. Participants whose liver laboratory tests fall outside the above ranges may be retested and, if the eligibility criteria are met on retesting, may be enrolled after confirmation by the Medical Monitor.
  • In addition, participants with abnormal laboratory results related to confirmed benign liver conditions including Gilbert's syndrome (defined by asymptomatic unconjugated hyperbilirubinemia [17 to 70 µmol/L or 1 to 4 mg/dL]) and asymptomatic gallstones, will be considered eligible for the study notwithstanding their abnormal laboratory results and may be enrolled.
  • Participant is currently on antiviral therapy for or C, or chronic/active hepatitis B or active evidenced by hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis B virus (HBV)-DNA positivity or hepatitis C virus (HCV)-RNA viral load positivity, respectively.
  • Negative viral load assays in 2 samples, collected at least 6 months apart, will be required to be considered negative. Both natural clearers and those who have cleared HCV on antiviral therapy are eligible. Participant has an active viral infection based on clinical observation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Initial Dose Cohort

    3x10\^13 vg/kg of AT845 administered via intravenous infusion

    Genetic: zocaglusagene nuzaparvovec

  • Experimental
    Second Dose Cohort

    6x10\^13 vg/kg of AT845 administered via intravenous infusion

    Genetic: zocaglusagene nuzaparvovec

  • Experimental
    Third Dose Cohort

    1x10\^14 vg/kg of AT845 administered via intravenous infusion

    Genetic: zocaglusagene nuzaparvovec

Interventions

  • Geneticzocaglusagene nuzaparvovec

    AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter

    Also known as: AT845

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability over time

    Frequency of adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests

    Time frame: Up to month 120

  2. GAA enzymatic activity

    Change from baseline in GAA enzymatic activity in muscle biopsies at week 12

    Time frame: Baseline and Week 12

  3. GAA protein expression

    Change from baseline in GAA protein expression in muscle biopsies at week 12.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Vector Copy Number

    Change from baseline in vector copy number (VCN) in muscle biopsies at week 12

    Time frame: Baseline and Week 12

  2. Thigh Fat Fraction

    Change from baseline in thigh fat fraction by MRI

    Time frame: Baseline and Month 18

  3. 6-Minute Walk Test (for ambulatory patients)

    Change from baseline in the distance walked in the 6 minute walk test (6MWT), which is a standardized assessment of how far an individual can walk on a hard, flat surface in a period of 6 minutes

    Time frame: Baseline, Week 24 and Week 48

  4. Percentage Predicted for 6-Minute Walk Test (for ambulatory patients)

    Change from baseline in percentage predicted for 6MWT, which is a standardized assessment of how far an individual can walk on a hard, flat surface in a period of 6 minutes

    Time frame: Baseline, Week 24 and Week 48

  5. Forced Vital Capacity (FVC)

    Change from baseline in percentage of predicted FVC measured by pulmonary function testing

    Time frame: Baseline, Week 24 and Week 48

  6. Maximum Inspiratory Pressure (MIP)

    Change from baseline in MIP measured by pulmonary function testing

    Time frame: Baseline, Week 24 and Week 48

  7. Maximum Expiratory Pressure (MEP)

    Change from baseline in MEP measured by pulmonary function testing

    Time frame: Baseline, Week 24 and Week 48

  8. The Gait, Stairs, Gower Maneuver, Chair (GSGC)

    The GSGC is a composite test that evaluates both the time to perform different motor activities and qualitatively measures motor function.

    Time frame: Baseline, Week 24 and Week 48

  9. Rasch-built Pompe-specific Activity (R-PAct) scale

    Change from baseline in the R-PAct scale, which was developed to measure Pompe patients' ability carry out daily life activities and social participation

    Time frame: Baseline and Week 48

  10. EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Questionnaire

    Change from baseline in health profiles and overall health status as assessed by the EQ-5D-5L

    Time frame: Baseline and Week 48

  11. Patient-Reported Outcomes Measurement Information System (PROMIS)

    Change from baseline in scores of PROMIS short forms for fatigue, physical function, social participation and sleep disturbance

    Time frame: Baseline and Week 48

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2020 (actual). Primary completion is estimated for Feb 2035, 172 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2019
First posted
Nov 22, 2019
StartActual
Oct 27, 2020
Primary completionEst.
Feb 28, 2035
CompletionEst.
Feb 28, 2035
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04174105
Responsible party
Sponsor
First posted
Nov 22, 2019
Start date
Oct 27, 2020
Primary completion
Feb 28, 2035 (estimated)
Completion
Feb 28, 2035 (estimated)
Last update
Nov 10, 2026

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion